Summary
Objective: Diabetic retinopathy, which leads to macular oedema and retinal neovascularisation, is the leading cause of blindness among working age Americans. Research has demonstrated significant cost savings associated with detection of eye disease in Americans and Europeans with insulin-dependent diabetes mellitus (IDDM, type I diabetes) and non-insulin-dependent diabetes mellitus (NIDDM, type II diabetes). In this report, we estimate the current and potential savings in both the United States and in a European country resulting from the screening and treatment of retinopathy in persons with diabetes.
Design: Computer modelling, incorporating data from population-based epidemiological studies and multicentre clinical trials. Monte Carlo simulation was used, combined with sensitivity analysis and present value analysis of cost savings.
Results: Detection and treatment of diabetic eye disease in both the United States and Scandinavia is not only cost effective, but is actually cost saving from the governmental perspective. Potential savings in the United States exceed $US600 million annually, while, in Sweden, potential savings of 36 million SEK might be realised. These findings are comparable given the differences in population between the 2 countries.
Conclusions: Our analysis indicates that prevention programmes aimed at improving eye care for persons with diabetes not only reduce needless vision loss, but also provide a financial return on the investment of public funds.
Similar content being viewed by others
References
Klein HA, Moorehead HB. Statistics on blindness in the model reporting area, 1969–1970. Bethesda (MD): US Dept of Health, Education & Welfare, 1973: DHEW Publ No. NIH 73–427 1970
National Society to Prevent Blindness. Vision problems in the US: a statistical analysis. New York: National Society to Prevent Blindness, 1980
Klein R, Klein BEK. Vision disorders in diabetes. National Diabetes Data Group Diabetes in America. Bethesda (MD): US Department of Health and Human Services, 1985. (NIH) Publ. No. 85–1468: Chapt. 8: 1–2
The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report No.8. Ophthalmology 1981; 88: 583–600
The Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. Arch Ophthalmol 1979; 97: 654–5
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report no. I. Arch Ophthalmol 1985; 103: 1796–806
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS Report no. 9. Ophthalmology 1991; 98: 766–85
Javitt JC, Aiello LP, Bassi LJ. et al. Detecting and treating retinopathy in patients with type I diabetes mellitus: savings associated with improved implementation of current guidelines. Ophthalmology 1991; 98: 1565–74
Ring A, Destefano F, Geiss L, et al. Centers for Disease Control community-based diabetes control program. In: Davidson JK, editor. Clinical diabetes mellitus: a problem-oriented approach. New York: Thieme, Inc. 1991: 728–37
Javitt JC, Canner JK, Frank RG, et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. Ophthalmology 1990; 97: 483–95
Canner JK, Chiang YP, Javitt JC. PROPHET: A Monte Carlo based simulation network model for a chronic progressive disease: the case of diabetic retinopathy. Proceedings of the Winter Simulation Conference 1992; 25: 1041–9
Dasbach E, Fryback D, Newcomb PN, et al. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 1991; 29: 20–39
CDC. Public Health Focus: Prevention of blindness associated with diabetic retinopathy. MMWR 1993; 42 (10): 191–5
Chiang Y, Bassi L, Javitt J. Federal budgetary costs of blindness. Milbank Q 1991; 70: 319–40
Fendrick AM, Javitt JC, Chiang YP. Cost-effectiveness of the screening and treatment of diabetic retinopathy: what are the costs of underutilization? Int J Technol Assess Health Care 1992; 8: 694–707
Everhart J, Knowler WC, Bennet PH. Incidence and risk factors for noninsulin-dependent diabetes. Diabetes in America, National Diabetes Data Group. NIH Publ No. 85–1468. Bethesda: US Dept of Health and Human Services, Public Health Service, National Institutes of Health, 1985: 1–5
Butler WJ, Ostrander JD, Carman WJ, et al. Diabetes mellitus in Tecumseh, Michigan. Am J Epidemiol 1982; 116: 971–80
Melton III LJ, Palumbo PJ, Chu CP. Incidence of diabetes mellitus by clinical type. Diabetes Care 1983; 6: 75–86
Klein R, Klein BEK, Moss SE. A population-based study of diabetic retinopathy in insulin-using patients diagnosed before 30 years age. Diabetes Care 1985; 8 Suppl. 1: 71–6
Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiology study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520–6
Klein BEK, Davis MD, Segal P, et al. Diabetic retinopathy: assessment of severity and progression. Ophthalmology 1984; 91: 10–7
Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiology study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107: 237–43
Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiology study of diabetic retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989; 107: 244–9
Clinical Trials Branch/Office of BiometrylNational Eye InstitutelNational Institutes of Health, analysis of early treatment of diabetic retinopathy study data, available from FL Ferris III, MD, National Institutes of Health
Blankenship GW. Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute’s patients participating in the Diabetic Retinopathy Study. Ophthalmology 1991; 98: 125–8
Vander JF, Duker JS, Benson WE, et al. Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 1991; 98: 1575–9
Ferris FL. How effective are treatments for diabetic retinopathy? JAMA 1993; 269: 1290–1
Vital Statistics of the United States 1988, United States Department of Health and Human Services, Public Health Services, Centers for Disease Control, National Center for Health Statistics. Vol. 1. Section 4: 17
Everhart J, Knowler WC, Bennet PH. Incidence and risk factors for non insulin-dependent diabetes. Diabetes in America, National Diabetes Data Group. Bethesda (MD): US Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1985; IV: 1–5
US Health Care Financing Administration. Average medicare allowable charges for specific ophthalmic procedures 1990. Available upon request from: Office of Statistics, Health Care Financing Administration
Weinstein MC, Statson WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716–21
Bradford OF. The choice of the discount rate for government investments. In: Haveman RH, Margolis J, editors. Public expenditure and policy analysis. 3rd ed. Boston: Houghton Mifflin Co. 1983; 129–44
Goldman L, Sia STB, Cook EF, et al. Cost and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988; 319: 152–7
Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health 1985; 6: 41–63
Discounting health care: only a matter of timing? [editorial]. Lancet 1992; 340: 148–9
Parsonage M, Neuburger H. Discounting and health benefits. Health Economics 1992; I: 71–6
Johannesson M. On the discounting of gained life-years in costeffectiveness analysis. Int J Technol Assess Health Care 1992; 8: 364–9
Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: VI. Retinal photocoagulation. Ophthalmology 1987; 94: 747–53
Witkin SR, Klein R. Ophthalmic care for persons with diabetes. JAMA 1984; 251: 2534–7
Brechner RJ, Cowie CC, Howie LJ, et al. Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA 1993; 270: 1714–8
Javitt JC, Ferris FL, Aiello LP, et al. Preventive eye care in people with diabetes is cost-saving to the federal government. Diabetes Care 1994; 17: 909–17
Sussman EJ, Tsiaras WG, Soper KA. Diagnosis of diabetic eye disease. JAM A 1982; 247: 3231–4
Moss SE, Klein R, Kessler SO, et al. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985; 92: 62–7
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Javitt, J.C. Cost Savings Associated with Detection and Treatment of Diabetic Eye Disease. Pharmacoeconomics 8 (Suppl 1), 33–39 (1995). https://doi.org/10.2165/00019053-199500081-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199500081-00008